Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: decided (352), settled (243), arranged (1000), approved (776), fixed (116), granted (180)

MyelomaMPTMelphalan(PO)PrednisoloneThalidomideVer1

Description: Chemotherapy Protocol MULTIPLE MYELOMA MPT-MELPHALAN (PO)-PREDNISOLONE-THALIDOMIDE Regimen Multiple Myeloma – MPT-Melphalan (PO)-Prednisolone-Thalido
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaMPTMelphalanPOPrednisoloneThalidomideVer1.pdf

MyelomaCTDa28CyclophosphamideDexamethasoneThalidomideAttenuated(CTDa)Ver1

Description: Chemotherapy Protocol MULTIPLE MYELOMA CTDa (28)-CYCLOPHOSPHAMIDE-DEXAMETHASONE-THALIDOMIDE (ATTENUATED) (CTDa-28) There are multiple versions of thi
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaCTDa28CyclophosphamideDexamethasoneThalidomideAttenuatedCTDaVer1.pdf

MyelomaCTD21CyclophosphamideDexamethasoneThalidomide(CTD)Ver1

Description: Chemotherapy Protocol MULTIPLE MYELOMA CTD (21)-CYCLOPHOSPHAMIDE-DEXAMETHASONE-THALIDOMIDE (21 days) There are multiple versions of this protocol in
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaCTD21CyclophosphamideDexamethasoneThalidomideCTDVer1.pdf

Myeloma VCD (SC35) bortezomib (SC) cyclophosphamide dexamethasone 35 day

Description: Chemotherapy Protocol MULTIPLE MYELOMA VCD (SC-35) - BORTEZOMIB (SC)-CYCLOPHOSPHAMIDE-DEXAMETHASONE (35 day) Regimen Multiple Myeloma – VCD (SC-35
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Myeloma-VCD-SC35-bortezomib-SC-cyclophosphamide-dexamethasone-35-day.pdf

Myeloma VCD (IV35) bortezomib (IV) cyclophosphamide dexamethasone 35 day

Description: Chemotherapy Protocol MULTIPLE MYELOMA VCD (IV-35) - BORTEZOMIB (IV)-CYCLOPHOSPHAMIDE-DEXAMETHASONE (35 day) Regimen Multiple Myeloma – VCD (IV-35
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Myeloma-VCD-IV35-bortezomib-IV-cyclophosphamide-dexamethasone-35-day.pdf

Pembrolizumab Ver 1 skin

Description: Chemotherapy Protocol SKIN CANCER Pembrolizumab Pembrolizumab is currently available on a compassionate use basis on
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/SkinPembrolizumabVer1.pdf

Nivolumab Ver 1.1 skin

Description: Chemotherapy Protocol SKIN CANCER Nivolumab This regimen may require funding. Regimen Skin – Nivolumab Indication The treatme
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/NivolumabVer1.1.pdf

Docetaxel (100) Ver 1.1

Description: Chemotherapy Protocol BREAST CANCER Regimen DOCETAXEL (100) Breast Cancer – Docetaxel (100) Indication Neoadjuvant / ad
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Docetaxel-100-Ver-11.pdf

Eisenmenger syndrome - patient information

Description: Eisenmenger syndrome is a form of congenital heart disease in which the pressure in the pulmonary (lung) arteries is high, causing
Url: /Media/UHS-website-2019/Patientinformation/Heartandlungs/Eisenmenger-syndrome-1579-PIL.pdf

Giving birth after a caesarean section - patient information

Description: We have written this factsheet to give you more information about the birth options available to you if you have had
Url: /Media/UHS-website-2019/Patientinformation/Pregnancyandbirth/Giving-birth-after-a-caesarean-section.pdf

461 to 470 of 509

Previous … 45 46 47 48 49 … Next